Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global biotechnology revolution, providing innovative solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for the Development of the Bioeconomy," indicating a trillion-yuan market potential in the bioeconomy [4][5] Market Performance - The Huazhong Synthetic Biology Index rose by 14.49% to 1709.48 during the week of July 14-18, 2025, outperforming the Shanghai Composite Index by 13.8 percentage points and the ChiNext Index by 11.32 percentage points [5][18] - The overall performance of synthetic biology stocks was strong, with the top six performing companies being all from the pharmaceutical sector, including Kanghong Pharmaceutical (+22%) and Zhejiang Zhenyuan (+19%) [20][23] Company Developments - China National Pharmaceutical invested approximately 6.8 billion yuan to acquire 95.09% of Lixin Pharmaceutical, enhancing its R&D capabilities in oncology [26] - New Fengming invested 100 million yuan in Hefei Lifeng Biotechnology to promote the industrialization of bio-based polyester PEF [26] - Sichuan Huanlong Ecological Technology received approval for a 1.5 billion yuan bamboo fiber project, expected to produce 250,000 tons of bleached bamboo pulp annually [27] - Cargill and HELM AG launched the world's largest bio-based BDO project in Iowa, with an investment of 300 million USD, showcasing the potential of bio-based materials in the chemical industry [29] Industry Financing - The synthetic biology sector has seen accelerated financing, with nearly 100 companies completing new funding rounds in 2025. Notable examples include Tuoxin Tiancheng, which raised nearly 40 million USD for T-cell immunotherapy product development [35] - Illimis Therapeutics completed a 58 billion KRW (approximately 42 million USD) B round financing to advance its Alzheimer's disease candidate [35] Research and Development - Fuhong Hanlin announced the completion of the first patient dosing of its innovative HER2 antibody HLX22 in the US, marking a significant milestone in cancer treatment [39] - He Yuan Biotechnology's plant-derived recombinant human serum albumin received approval, representing a breakthrough in the field of plant-based recombinant protein drugs [39]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company plans to invest 100 million RMB in Lif Biotechnology, acquiring a 7.0175% stake, which is a strategic move to position itself in the bio-based polyester industry chain [6][7] - Lif Biotechnology is a leading manufacturer of bio-based FDCA, a key material in the "green chemistry" sector, which has the potential to replace petrochemical-based PET in the long term [6][7] - The investment is expected to create synergies with the company's existing polyester business, despite short-term challenges such as the target company's losses and industrialization risks [7] Financial Summary - The company’s projected net profits for 2025, 2026, and 2027 are 1.344 billion, 1.845 billion, and 2.234 billion RMB respectively, with corresponding P/E ratios of 12.65, 9.21, and 7.61 [8] - Revenue is expected to grow from 67.091 billion RMB in 2024 to 81.610 billion RMB in 2027, with a compound annual growth rate (CAGR) of approximately 6.5% [11] - The gross margin is projected to improve from 5.6% in 2024 to 7.5% in 2027, indicating enhanced profitability [11]

Core Viewpoint - The bio-basedlink platform is officially launched to provide precise and efficient supplier matching services for the bio-based and biomanufacturing industry, featuring four main categories: industry news, research reports, new product database, and supply-demand database [1]. Group 1: Platform Features - The new product database includes eight subfields such as materials, energy and chemicals, synthetic biology, and biomanufacturing [1]. - The supply-demand database covers upstream and downstream demand, supply, technology achievements, and talent matching [1]. - Companies can join the new product database to gain a dedicated company page showcasing their logo, positioning, product keywords, and advantages, with free updates available for information changes [4]. Group 2: Accessing the Platform - Users can find the official website by following the WeChat public account "Synthetic Biology and Green Biomanufacturing" or by searching for www.bio-basedlink.net [2]. - Companies that have participated in relevant activities can join the new product database for free, and DT members receive priority recommendations for one year of platform cooperation [8]. Group 3: Supply-Demand Database - The supply-demand database allows users to publish and match their industry needs, including products, technologies, and talents [10]. - The platform will collect and publicly share information on industry "new technological achievements" and "end-user brand demands" [10]. Group 4: Research and Reports - The DT Industry Research Institute will publish monthly, quarterly, and annual reports on the bio-based and biomanufacturing industry, providing insights based on real-time information and industry surveys [14]. - The platform aims to help users maintain a competitive edge through systematic and in-depth observations and research [15]. Group 5: Marketing and Exposure - New products and related articles will be promoted across various channels, including the bio-basedlink platform website and multiple WeChat public accounts [16]. - The platform aims to facilitate exposure and networking opportunities for companies in the bio-based materials sector [17].